- Home
- BEAM vs MLNK Comparison
BEAM vs MLNK Comparison
Compare BEAM & MLNK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- MLNK
- Stock Information
- Founded
- BEAM 2017
- MLNK 1998
- Country
- BEAM United States
- MLNK United States
- Employees
- BEAM N/A
- MLNK N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- MLNK Computer Software: Prepackaged Software
- Sector
- BEAM Health Care
- MLNK Technology
- Exchange
- BEAM Nasdaq
- MLNK Nasdaq
- Market Cap
- BEAM 1.6B
- MLNK 1.3B
- IPO Year
- BEAM 2020
- MLNK 2021
- Fundamental
- Price
- BEAM $20.90
- MLNK $17.14
- Analyst Decision
- BEAM Strong Buy
- MLNK Hold
- Analyst Count
- BEAM 11
- MLNK 7
- Target Price
- BEAM $48.90
- MLNK $20.64
- AVG Volume (30 Days)
- BEAM 2.0M
- MLNK 417.7K
- Earning Date
- BEAM 08-05-2025
- MLNK 08-07-2025
- Dividend Yield
- BEAM N/A
- MLNK N/A
- EPS Growth
- BEAM N/A
- MLNK N/A
- EPS
- BEAM N/A
- MLNK N/A
- Revenue
- BEAM $63,578,000.00
- MLNK $319,970,000.00
- Revenue This Year
- BEAM N/A
- MLNK $6.24
- Revenue Next Year
- BEAM $8.82
- MLNK $5.85
- P/E Ratio
- BEAM N/A
- MLNK N/A
- Revenue Growth
- BEAM N/A
- MLNK 5.15
- 52 Week Low
- BEAM $13.53
- MLNK $15.49
- 52 Week High
- BEAM $35.25
- MLNK $25.33
- Technical
- Relative Strength Index (RSI)
- BEAM 72.82
- MLNK 56.23
- Support Level
- BEAM $19.02
- MLNK $16.09
- Resistance Level
- BEAM $20.46
- MLNK $17.41
- Average True Range (ATR)
- BEAM 1.07
- MLNK 0.48
- MACD
- BEAM 0.52
- MLNK 0.10
- Stochastic Oscillator
- BEAM 95.54
- MLNK 85.94
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About MLNK MeridianLink Inc.
MeridianLink Inc is a cloud-based software solution for financial institutions, including banks, credit unions, mortgage lenders, specialty lending providers, and consumer reporting agencies. It generates maximum revenue from Lending Software Solutions.